Malignant Glomus Tumors

Manolidis, Spiros; Shohet, Jack A.; Jackson, C. Gary; Glasscock, Michael E.

doi:10.1097/00005537-199901000-00007

Cited by 138 publications

(79 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1941, Guild first described "glomic tissue" in temporal bone as a vascular tissue in the dome of the [4]. Catecholamine secreting or "functional" tumours occur in 1%-3% of cases.…”

Section: Discussionmentioning

confidence: 99%

Glomus Tympanicum

Singh

Badhwar

D’Souza

et al. 2004

Medical Journal Armed Forces India

View full text Add to dashboard Cite

“…In 1941, Guild first described "glomic tissue" in temporal bone as a vascular tissue in the dome of the [4]. Catecholamine secreting or "functional" tumours occur in 1%-3% of cases.…”

Section: Discussionmentioning

confidence: 99%

Glomus Tympanicum

Singh

Badhwar

D’Souza

et al. 2004

Medical Journal Armed Forces India

View full text Add to dashboard Cite

“…Immunohistochemical evaluation of SDHB may be used to screen for possible hereditary association as in PGLs of other sites. Distant metastasis may occur in up to 5% of cases and appears more common in hereditary cases [39].…”

Section: Hnpgl Sites Of Involvementmentioning

confidence: 99%

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas

Williams

Tischler

2017

Head and Neck Pathol

View full text Add to dashboard Cite

“…1,15 Previous findings have indicated that malignancy is least common (2-4%) for jugulo-tympanic tumors, approximately 6% for carotid body tumors, 1,11 and 16 -19% for vagal tumors. 16,17 Although the majority of paragangliomas are benign (i.e., do not metastasize), the preoperative assessment and surgical plan for this tumor should include evaluation for metastases and a plan that addresses treatment of the primary site and possible metastases. For paragangliomas without clinical evidence of lymphadenopathy, removal of adjacent regional lymph nodes is recommended to identify possible occult metastases that would reclassify the tumor as malignant.…”

mentioning

confidence: 99%

National Cancer Data Base report on malignant paragangliomas of the head and neck

Lee¹,

Barich²,

Karnell³

et al. 2002

Cancer

367

351

View full text Add to dashboard Cite

BACKGROUNDMalignant paragangliomas of the head and neck are rare, with previous reports limited to nine or fewer patients. The current review included 59 cases extracted from the National Cancer Data Base that were diagnosed between 1985–1996.METHODS The primary criterion for inclusion in the current study was verified metastatic spread from a paraganglioma of the head and neck. Patterns of presentation and treatment as well as clinically relevant associations were demonstrated in contingency tables. Relative survival was used for analysis of outcome.RESULTSThe average patient age at presentation was 44 years, and gender distribution was equivalent. Metastases were confined to regional lymph nodes in the majority of cases (68.6%), with carotid body tumors found to have an even higher rate of regional confinement (93.8%). Surgery was the most common treatment (76.3%). The use of adjuvant irradiation for regionally confined disease increased across time, from 27% (1985–1990) to 46% (1991–1996). The 5‐year relative survival rate was 59.5% (76.8% for regionally confined carcinoma and 11.8% for distant metastasis). Among patients who were followed until death, those treated with adjuvant irradiation had a longer median survival (45 months) compared with those patients who were treated with surgery alone (12 months).CONCLUSIONS Malignant paraganglioma represents metastatic spread of a tumor type that, when restricted to the site of origin, is considered benign. Metastases from malignant paragangliomas of the head and neck usually are regionally confined. The primary management of a recognized malignancy should be directed toward complete surgical removal of the primary tumor and regional lymph nodes. Postoperative irradiation may be beneficial in slowing the progression of residual disease. Cancer 2002;94:730–7. © 2002 American Cancer Society.DOI 10.1002/cncr.10252

show abstract

Malignant Glomus Tumors

Abstract: This rate of malignancy should advocate against a watchful, waiting approach. Radiation therapy is not advocated as a primary modality for this type of tumor, as it may lead to recurrence/persistence with either subsequent malignant degeneration and metastases or local recurrence.

Cited by 138 publications

References 42 publications

Glomus Tympanicum

Glomus Tympanicum

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas

National Cancer Data Base report on malignant paragangliomas of the head and neck

Contact Info

Product

Resources

About